Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.

News > Community news > Crick spinout to begin first-in-human clinical study for leukaemia

Crick spinout to begin first-in-human clinical study for leukaemia

GammaDelta Therapeutics has received Investigational New Drug approval from the US FDA for their GDX012 cell therapy to be investigated as a treatment for blood cancers. 
7 Jun 2021
United States of America
Community news

Featured

Clinicians

To view this News Article please log in or create a profile

Similar stories

We are delighted to announce that Patti Biggs, our Information Services Specialist, has been awarded a Highly Commended Award from the Hidden REF. More...

Congratulations to group leader Alessandro Costa, who has been awarded a Wellcome Discovery Award for £3m over eight yea… More...

We are delighted to confirm that David (Dave) Allen will be joining the Crick as our new Director of Translation in Janu… More...

Congratulations to group leader Lucia Prieto-Godino, who has been selected as a European Molecular Biology Organisation … More...

Have your say

 
image

Contact us

The Francis Crick Institute
1 Midland Road
London
NW1 1AT

connect@crick.ac.uk


This website is powered by
ToucanTech